Flag of the European Union EU Clinical Trials Register Help

Clinical trials for MASS syndrome

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    574 result(s) found for: MASS syndrome. Displaying page 29 of 29.
    «« First « Previous 21  22  23  24  25  26  27  28  29 
    EudraCT Number: 2007-003560-21 Sponsor Protocol Number: REAL 07 CC5013 STUDY ID LR-CHOP21 Start Date*: 2007-09-20
    Sponsor Name:GIMURELL
    Full Title: Prospective multicenter phase I-II pilot trial to evaluate efficacy and safety of treatment with Lenalidomide plus R-CHOP21 (LR-CHOP21) for elderly patients with untreated Diffuse Large B-Cell Lymp...
    Medical condition: patient with BDLCL elderly untreated
    Disease: Version SOC Term Classification Code Term Level
    6.1 10012825 PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004739-58 Sponsor Protocol Number: BAN2401-G000-301 Start Date*: 2019-06-12
    Sponsor Name:Eisai Limited
    Full Title: A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer’s Disease
    Medical condition: Mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    20.0 10029205 - Nervous system disorders 10074616 Prodromal Alzheimer's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) SE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003159-12 Sponsor Protocol Number: J4B-MC-OKAA Start Date*: 2021-12-24
    Sponsor Name:Prevail Therapeutics, a wholly-owned subsidiary of Eli Lilly and Company
    Full Title: A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of LY3884963 in Patients with Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN) (PROCLAIM)
    Medical condition: Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10068968 Frontotemporal dementia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) ES (Temporarily Halted) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-004800-40 Sponsor Protocol Number: AT1001-041 Start Date*: 2012-01-25
    Sponsor Name:Amicus Therapeutics, Inc.
    Full Title: An Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects with Fabry Disease.
    Medical condition: Fabry disease is a rare X-linked lysosomal storage disorder caused by mutations in the gene (GLA) that encodes the lysosomal enzyme α-galactosidase A.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) IT (Completed) DK (Completed) BE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000065-16 Sponsor Protocol Number: DS102A-07-CV1 Start Date*: 2020-08-11
    Sponsor Name:Afimmune Ltd.
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Dose Finding Phase IIb Study to Assess the Efficacy and Safety of Orally Administered Epeleuton in Patients with Hypertriglyceridemia and Type 2 Diab...
    Medical condition: Hypertriglyceridemia and Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.1 10027433 - Metabolism and nutrition disorders 10020870 Hypertriglyceridemia LLT
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LV (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000727-13 Sponsor Protocol Number: MRG106-11-201 Start Date*: 2018-12-17
    Sponsor Name:miRagen Therapeutics, Inc.
    Full Title: SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects with Cutaneous T-Cell Lymp...
    Medical condition: Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004864 10028483 Mycosis fungoides LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) BE (Completed) ES (Prematurely Ended) DE (Completed) AT (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-006062-36 Sponsor Protocol Number: NW-3509/008A/II/2020 Start Date*: 2021-06-30
    Sponsor Name:Newron Pharmaceuticals S.p.A.
    Full Title: A PHASE II/III, PROSPECTIVE, MULTI-CENTER, RANDOMIZED, 4-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, DESIGNED TO DETERMINE THE SAFETY, TOLERABILITY, EEG EFFECTS AND EFFICACY OF ORAL DOSES OF 30 M...
    Medical condition: Chronic schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) CZ (Completed) ES (Ongoing) RO (Ongoing) HU (Completed) PL (Completed) EE (Completed) LV (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000184-40 Sponsor Protocol Number: 20130173 Start Date*: 2014-09-11
    Sponsor Name:Amgen, Inc.
    Full Title: Prospective, Multicenter, Single-arm Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Denosumab in Children With Osteogenesis Imperfecta
    Medical condition: Osteogenesis Imperfecta
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10031243 Osteogenesis imperfecta PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) ES (Completed) Outside EU/EEA BG (Completed) PL (Prematurely Ended) BE (Completed) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000236-22 Sponsor Protocol Number: Study_protocol_CODEX-P_ver2_1 Start Date*: 2020-12-16
    Sponsor Name:Chronic Obstructive Pulmonary Disease Trial Network (COP:TRIN)
    Full Title: COPD EXacerbation and Pulmonary hypertension Trial - The effect of Sildenafil treatment to patients with COPD exacerbation and pulmonary hypertension
    Medical condition: This study will investigate treatment of patients with chronic obstructive pulmonary disease (COPD), who experience frequent exacerbations (AECOPD). Only patients with a minimum of 2 moderate AECOP...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004854 10019203 Head spinning LLT
    20.1 100000004852 10033405 Pain head LLT
    20.0 100000004852 10019218 Headache NOS LLT
    20.1 100000004856 10000460 Acid dyspepsia LLT
    22.1 100000004856 10013947 Dyspepsia aggravated LLT
    20.0 100000004856 10013948 Dyspepsia and other specified disorders of function of stomach LLT
    21.1 100000004856 10019328 Heartburn-like dyspepsia LLT
    20.1 100000004856 10064536 Functional dyspepsia LLT
    23.1 100000004856 10012727 Diarrhea LLT
    20.0 100000004859 10023222 Joint pain LLT
    21.0 100000004859 10025012 Lumbo-sacral pain LLT
    21.1 100000004859 10028322 Muscle pain LLT
    20.0 100000004856 10033394 Pain epigastric LLT
    21.1 100000004866 10016046 Facial flushing LLT
    20.0 100000004853 10013614 Double vision LLT
    21.0 100000004848 10005604 Blood in urine LLT
    20.0 100000004872 10018801 Gynecomastia LLT
    20.0 100000004872 10060603 Hematospermia LLT
    20.0 100000004851 10002272 Anemia LLT
    22.1 100000004853 10034961 Photophobia aggravated LLT
    20.0 100000004871 10023139 Jaundice NOS LLT
    20.0 100000004853 10030042 Ocular hyperemia LLT
    20.1 100000004853 10051304 Retinal bleeding LLT
    20.1 100000004853 10005889 Blurry vision LLT
    20.1 100000004856 10046272 Upper abdominal pain LLT
    20.0 100000004856 10038263 Reflux oesophagitis LLT
    20.0 100000004856 10047706 Vomiting NOS LLT
    20.0 100000004867 10016558 Fever LLT
    21.1 100000004862 10024969 Lower respiratory tract infection NOS LLT
    20.0 100000004859 10048317 Myalgia aggravated LLT
    21.1 100000004859 10003990 Back pain (without radiation) LLT
    20.1 100000004852 10020922 Hypesthesia LLT
    20.0 100000004852 10027605 Migraine NOS LLT
    21.1 100000004852 10044572 Tremor limb LLT
    20.1 100000004852 10044570 Tremor finger LLT
    20.0 100000004873 10002856 Anxiety attack LLT
    20.0 100000004873 10022442 Insomnia NOS LLT
    20.0 100000004855 10011232 Coughing LLT
    20.0 100000004862 10040756 Sinusitis NOS LLT
    20.0 100000004867 10014210 Edema LLT
    20.0 100000004867 10014211 Edema (NOS) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001756-36 Sponsor Protocol Number: MO18264 Start Date*: 2005-02-22
    Sponsor Name:LYSA (The Lymphoma Study Association)
    Full Title: A multicentre, phase III, open-label, randomized study in patients with advanced follicular lymphoma evaluating the benefit of maintenance therapy with rituximab (Mabthéra® ) after induction of res...
    Medical condition: Follicular lymphoma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10029473 Nodular (follicular) lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) FI (Completed) CZ (Completed) PT (Completed) GB (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-024423-24 Sponsor Protocol Number: AB10015 Start Date*: 2013-01-29
    Sponsor Name:ABScience
    Full Title: A prospective, multicenter, randomized, double-blind, placebocontrolled, parallel group, phase 2 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients su...
    Medical condition: patients suffering from Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GR (Completed) SK (Prohibited by CA) IT (Completed) HU (Completed) PT (Completed) IE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-016178-33 Sponsor Protocol Number: 1245.25 Start Date*: 2010-11-12
    Sponsor Name:Boehringer Ingelheim B.V.
    Full Title: A Phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in ...
    Medical condition: The study will be performed in patients with type 2 diabetes mellitus and high cardiovascular risk who have insufficient glycaemic control despite diet and exercise and are either treatment naïve o...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067585 Type 2 diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed) ES (Completed) BE (Completed) FR (Completed) IT (Completed) HU (Completed) PT (Completed) GB (Completed) AT (Completed) GR (Completed) PL (Completed) EE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2006-000658-27 Sponsor Protocol Number: D5130C05262 Start Date*: 2006-12-12
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute C...
    Medical condition: non-ST and ST elevation acute coronary syndromes (ACS)
    Disease: Version SOC Term Classification Code Term Level
    9 10011085 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed) PT (Completed) HU (Completed) DE (Completed) FR (Completed) SE (Completed) AT (Completed) NL (Completed) DK (Completed) SK (Completed) BE (Completed) CZ (Completed) GR (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-003202-14 Sponsor Protocol Number: PCYC-1141-CA Start Date*: 2017-04-12
    Sponsor Name:Pharmacyclics LLC
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination wit...
    Medical condition: Follicular lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10029473 Nodular (follicular) lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) CZ (Trial now transitioned) HU (Trial now transitioned) PT (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned) AT (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 21  22  23  24  25  26  27  28  29 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 17 12:23:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA